Scientists at Klick Applied Sciences say they discovered a way to use a continuous glucose monitor (CGM) as a diabetes screening tool. The scientists determined that they can use artificial intelligence (AI) to screen and prevent the chronic health condition. They used machine learning and 12 hours of data from CGMs to determine whether a […]
Research & Development
Stanford researchers say they cured diabetes in mice
A Stanford Medicine study observed the apparent curing of diabetes in mice following transplantation of insulin-secreting pancreatic islet cells. Researchers say the animals’ immune systems accepted the donated cells prior to transplantation. This occurs through a three-pronged process they say they could easily replicate in humans. The mice did not need immune-suppressing treatments after the […]
Rani Therapeutics launches RT-111 development program
Robotic pill company Rani Therapeutics (Nasdaq:RANI) has begun developing RT-111, a RaniPill GO capsule containing a biosimilar of Johnson & Johnson’s (NYSE:JNJ) Stelara (ustekinumab). The company anticipates that RT-111 could potentially treat psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis. The FDA first approved Stelara in 2009 for psoriasis. Stelara is available in intravenous and […]
GlucoTrack to begin R&D for new long-term CGM
GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with a R&D program for a long-term continuous glucose monitor (CGM). Rutherford, New Jersey-based GlucoTrack said it recently required related IP. It now intends to develop a long-term, implantable glucose management platform for the type 1 diabetes market. Initial data gives the company confidence […]
This robotic capsule could deliver large-protein drugs like insulin
Researchers at the Massachusetts Institute of Technology (MIT) developed a new drug capsule with a robotic cap for improved drug delivery. Large-protein drugs generally can’t pass through the mucus barrier that lines the digestive tract. Insulin and most other “biologic drugs” with proteins or nucleic acids thus must be injected or administered in a hospital, […]
Rapid Dose closes first tranche of $5M financing
Rapid Dose Therapeutics announced today that it closed on the first tranche of a previously announced private placement financing. Burlington, Ontario-based Rapid Dose develops drug delivery products, including the flagship QuickStrip thin, orally dissolvable film that was designed to be infused with a number of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered […]
MIT researchers think microparticles could deliver ‘self-boosting’ vaccines
MIT researchers are touting microparticles that can deliver payloads at different points, potentially creating “self-boosting” vaccines. A new study, highlighted on the institute’s news website, demonstrates a way in which researchers could design vaccines that would need to be given just once before they “self-boost,” or essentially re-deliver the therapeutic, at a specified point in […]
Diabeloop, SOOIL partner on automated insulin delivery technology
Diabeloop announced today that it entered into global development and commercial agreements with insulin delivery technology developer SOOIL. Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020. According to a news […]
Ariste Medical co-founder sees great potential for drug-coated implants and orthopedics
It’s been more than a decade since Lisa Jennings launched not one but two companies in the Great Recession. In 2020, she sold CirQuest Labs to MLM Medical Labs, where Jennings serves as chief scientific officer and managing director of U.S. operations. More recently, her pre-commercial medtech development startup, Ariste Medical, won FDA 510(k) approval for […]
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]
